Navigation Links
BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

- First in human clinical data highlight safety profile of BSI-201 in

subjects with advanced solid tumors -

BRISBANE, Calif., May 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that data supporting its lead PARP inhibitor, BSI-201, will be presented at the 2008 American Society of Clinical Oncology annual meeting in Chicago.

Findings will be presented from the first in human Phase 1 study of BSI-201, a small-molecule inhibitor of poly-ADP-ribose polymerase (PARP), as a monotherapy in subjects with advanced solid tumors. BiPar will also present a Phase 1b study evaluating BSI-201 in combination with topotecan, gemcitabine, temozolomide and carboplatin/paclitaxel in subjects with advanced solid tumors. The primary objective of these respective studies is to assess the safety profile of BSI-201 when used as a monotherapy and in combination with cytotoxic chemotherapy in subjects with measurable disease.

The schedule of poster presentations is as follows:

Title: First in Human Phase 1 Study of BSI-201, a Small Molecule

Inhibitor of Poly ADP-ribose polymerase (PARP) in Subjects with

Advanced Solid Tumors

When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session

Abstract#: 3577

Title: A Phase 1B Study Evaluating BSI-201 in Combination with

Chemotherapy in Subjects with Advanced Solid Tumors

When: Monday, June 2, 2008, 2-6 PM; Molecular Therapeutics Session

Abstract #: 3579

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potent
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
5. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
6. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009).... 20 Reportlinker.com announces th...s catalogue. ,, Global Markets for Assisted Re...linker.com/p0164742/Global-Markets-for-Assisted-Re...&utm_medium=pr&utm_campaign=prnewswire ,...rs the U.S., 15 Countries in Europe and Japan. Thi...
(Date:11/20/2009)...G, Pa., Nov. 20 In resp...stions why currently available medications designe...red, ECRI Institute, an independent nonprofit orga... Finasteride for Prevention of Prostate Cancer f...New York Times article, " Drugs to Deter Some Can...
(Date:11/19/2009)..., Nov. 19 BioCryst Pharm...the pricing of a public offering of 5,000,000 shar...ng in gross proceeds of $48.75 million. All of th... an effective shelf registration statement previou...ion. BioCryst has also granted the underwriters a...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Celleration Appoints Mark T Wagner President and Chief Executive Officer 50572 1Celleration Appoints Mark T Wagner President and Chief Executive Officer 50572 2New Partnership Between FirstCare and HealthFitness Provides Cost Effective Preventive Health Solutions for Small to Mid Size Companies 50570 1New Partnership Between FirstCare and HealthFitness Provides Cost Effective Preventive Health Solutions for Small to Mid Size Companies 50570 2New Partnership Between FirstCare and HealthFitness Provides Cost Effective Preventive Health Solutions for Small to Mid Size Companies 50570 3New Partnership Between FirstCare and HealthFitness Provides Cost Effective Preventive Health Solutions for Small to Mid Size Companies 50570 4Hard To Treat Diseases 28HTDS 29 Clinical Trial Update on Therapeutic effects of Combined Treatment With Ribavirin And Tiazofurin 50568 1Hard To Treat Diseases 28HTDS 29 Clinical Trial Update on Therapeutic effects of Combined Treatment With Ribavirin And Tiazofurin 50568 2
...ept. 6 Terumo Heart Inc. announced,today that it ...opean,Association of Cardio-Thoracic Surgeons (EAC... 2007. (Logo: http://www.newscom.com/cgi-bin/prn...m.com/cgi-bin/prnh/20070227/CLTU043LOGO ) A summ... company,s,DuraHeart(TM) Left Ventricular Assist S...
...ompany through end of clinical trial, MINNEAPOLIS...l device company, announced today that it has comp...Healthcare Vintage Fund led the round along,with s... including Prism,Venture Partners, the lead from t...has raised approximately $45 million in capital. ...
Other Medicine Technology:Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September 2Atritech Announces Completion of a $22 Million Equity Financing 2
(Date:11/22/2009)...In a new study, the amount of television viewed by...s the previous estimates of early childhood screen...significantly more on average than those in center...ne screen time in child care settings in more than...168 child care programs in four states, and was gu...
(Date:11/22/2009)... The Onder Law Firm’s...to those or families of those who may have experie...problems after taking XOLAIR. , ...The Onder Law Firm are among attorneys offering f...s such as heart attack and stroke. The attorneys ...
(Date:11/22/2009)... WASHINGTON, D.C. November 18, 2009 -- When peopl...parasites, which enter the body from the saliva of...pread to red blood cells. Inside the blood cells, ...dhesive proteins on the cell surface that change t.... , Experiments show that infected red blood cel...
(Date:11/22/2009)...NEW YORK (Nov. 22 2009) -- Physician-scientists fr... molecular mechanism that may prove to be a powerf...oma, a type of cancer that affects lymphocytes, or...researchers have been able to powerfully suppress ...s. , Promising results have led to the design of...
(Date:11/22/2009)...anning ahead can help keep eating under control, e...y News) -- The holiday season means you,ll be face...on. While some people simply give in and eat too m..., But there are ways to navigate between overindu..., manager of Nutrition Consult Services at Brigham...
Breaking Medicine News(10 mins):Health News:Daycare may double TV time for young children, study finds 2Health News:Daycare may double TV time for young children, study finds 3Health News:Daycare may double TV time for young children, study finds 4Health News:The Attorneys of The Onder Law Firm Offers Free XOLAIR Case Review 2Health News:Measuring and modeling blood flow in malaria 2Health News:New cancer target for non-Hodgkin's lymphoma 2Health News:Go Healthy, Not Hungry for Holiday Eating 2
...ells in cord blood more than 30-fold , , F...ses natural killer (NK) immune system cells from u...kemia cells in mice, researchers say. , The NK ce... human leukemias, according to the study. , The f...
...Griffiths School of Nursing and Midwifery, has won...ustralian Nursing Awards. , Professor Rickard wo...d loss during testing procedures, reducing the ris...ntertainment complex. , Nurses routinely take bl...
...at,Corporation announced today a partnership with ...o its healthcare clients. In addition,RediStat is ...service in,conjunction with America,s Emergency Ne...., "We are very pleased to be associated with ALE...
...y Residents to Eat Right, Move More and ..., May 16 The last decade can be defined,by the up...o go in and out,of fashion like shoulder pads and ...., A new campaign crossing the country, the Campa...
...icacy of first FDA-approved nebulized formoter...PD -, NAPA, Calif., May 16 Dey, L.P. announced t...e given at the International,Conference of the Ame... COPD symptoms of using Perforomist(TM),Inhalation...
... in the North Central Cancer Treatment Group (NCCT...s calcium and magnesium before and after the chemo...nced colon cancer experience a significantly reduc...ull course of treatment. The findings were releas...
Other Medicine News:Health News:New Therapy Kills Human Leukemia Cells in Mice 2Health News:Research talent wins national Innovation in Nursing award 2Health News:RediStat Corporation Partners With ALERT FM for Disaster-Proof Emergency Communications 2Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 2Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 3Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 4Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 5Health News:Study shows that administering calcium and magnesium effectively reduces neurological sensitivity 2
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products: